23andMe Inc. (ME): Expected Profit

23andMe Inc. (ME) - corporate logo

Risks for 23andMe Holding Co. (ME) are mitigated by a combination of B2C test sales and B2B partnerships with pharma giants. The forward earnings indicator visualizes these processes, where the value of expresses the metric level. Moderate biotech sector cyclicity and long drug development cycles provide stability. Growth potential is embedded in the transition to AI analytics and paid subscriptions for genetic reports.

ME: 23andMe Holding Co. Company Profit Forecast 07/04/2022 - 11/18/2026

Analytical breakdowns for 23andMe Holding Co.

- stock quotes and analyst forecast:
- stock exchange capitalization data:
Basic company analysis:ME, 23andMe Inc.
Core merchandise of 23andMe Holding Co

The monetization of the largest genetic data archive of 23andMe Holding Co. (ME) transforms static information into a long-term asset for medicine. The current calculated level of reflects the market valuation of this database's ability to generate cash flow. This metric aggregates consensus net income forecasts, separating speculative noise from fundamental value. The indicator's growth confirms the capitalization of intellectual property. By analyzing the expected earnings growth, an investor determines the risk of overpaying for the asset.